Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.
Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.
Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.
Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.